BCAS4

Across TCGA pan-cancer cohorts, BCAS4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BCAS4 data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher BCAS4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BCAS4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

COAD, CESC, and LUAD are the cancer types where BCAS4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.001	0.871	<.001	13	view →
CESC	DFS	Median	II,III,IV	0.184	0.705	.036	12	view →
LUAD	OS	Median	II,III,IV	0.266	0.749	.027	6	view →
UCEC	OS	Median	All	1.000	0.662	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BCAS4–COAD (OS)

Open the COAD breakdown →